mutation; however, resistance or intolerance can develop in some cases. 7 New treatment options are required for patients with ponatinib failure.
We previously reported medium-chain fatty-acid derivative AIC-47 as a novel anti-cancer agent for the treatment of CML. 8, 9 AIC-47 induces autophagic cell death through transcriptional suppression of BCR-ABL and perturbation of cancer-specific energy metabolism, including the Warburg effect. 8 TKI inhibit phosphorylation of BCR-ABL protein only, whereas AIC-47 suppresses expression of BCR-ABL itself through transcriptional suppression of the BCR-ABL gene. 8, 9 This suggests that AIC-47 could affect BCR-ABL-mutant cells.
Cancer cells efficiently use a limited energy source by modulating cellular signaling and reprogramming metabolic pathways. 10 These alterations including the Warburg effect confer many advantages to cancer cells, including the promotion of biosynthesis, ATP generation, detoxification and support of rapid proliferation. 11 The Warburg effect is a well-known metabolic switch that is partly achieved through regulated expression of pyruvate kinase muscle isoforms PKM1 and PKM2. 12 These isoforms are expressed by alternative splicing of the PKM mRNA precursor. 12 PKM is alternatively spliced to produce either the PKM1 or the PKM2 isoform, which contains exon 9 or exon 10, respectively. 13, 14 Previous studies showed that heterogeneous nuclear ribonucleoproteins (hnRNP) (ie, polypyrimidine tractbinding protein 1 [PTBP1, also known as hnRNPI], hnRNPA1, and hnRNPA2) are alternative splicing repressors of PKM1 14, 15 and that serine/arginine-rich protein SRSF3 activates PKM2 expression. 16, 17 We found that knockdown of BCR-ABL leads to perturbation of the Warburg effect through the hnRNP/PKM cascade. 8 We have already shown that AIC-47 showed cytotoxicity in wild type (WT)-BCR-ABL-harboring cells and leukemia stem cells; 8, 9 however, the effects on BCR-ABL-mutated cells have not been clarified.
Our previous data suggested that the effects of AIC-47 were independent of the configuration of BCR-ABL kinase. 9 In the present study, we examined the efficacy of AIC-47 in mutated-BCR-ABLharboring cells in vitro and in vivo.
| MATERIAL S AND ME THODS

| Patient blood samples
Blood samples from newly diagnosed CML patients were collected following protocol approval by the institutional review board of Kobe University and with informed consent.
| Cell culture and treatment
WT-, M351T-, Y253F-or T315I-BCR-ABL-transformed clones of mouse pro-B Baf3 cells (Baf3p210 cells) were gifted from Brian J.
Druker, Oregon Health and Science University Cancer Institute.
18
WT-BCR-ABL positive human ALL cell line TCCY was established as reported previously. 19 To establish imatinib-resistant clone having T315I-mutated BCR-ABL, the WT-BCR-ABL-harboring TCCY cells were treated with imatinib by gradually increasing the concentration (3-20 μM). The dead cells were washed out every 3 to 4 days, and the resistant subclones were isolated by limit- 
| Real-time RT-PCR
Total RNA was isolated from cells by using a NucleoSpin miRNA kit (TaKaRa, Otsu, Japan) according to the manufacturer's protocol.
Expression levels of mRNAs were determined as described previously. 
| Western blotting
Protein extraction and western blotting experiments were carried out as described previously. 9 Antibodies against the following proteins were purchased from Cell Signaling Technology (Danvers,
(#4053), and PKM1/2 (#3190). Anti-SRSF3 antibody (PN080PW) was obtained from MBL (Nagoya, Japan). The loading control was prepared by reincubating the same membrane with anti-β-actin antibody (A5316; Sigma-Aldrich).
| Transfections
Cells were transfected with siRNA for PTBP1 (siR-PTBP1; 5′-AUCUCUGGUCUGCUAAGGUCACUUC-3′; Invitrogen), hnRNPA1
(siR-hnRNPA1; sc-270345; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or SRSF3 (siR-SRSF3; 5′-UUACACGGCAGCCACAUAGUG UUCU-3′; Invitrogen) by using Lipofectamine RNAiMAX (Invitrogen)
according to the manufacturer's protocol. Sequence of the nonspecific control RNA (Hokkaido System Sciences, Sapporo, Japan) was 5′-GGCCUUUCACUACUCCUCA-3′. Collection of spleen and liver samples was done on day 18.
| Animal experiments
| Statistical analysis
Each examination was carried out in triplicate. Data are presented as means ± SD. Unless otherwise stated, differences were statistically evaluated by use of one-way ANOVA followed by t test. Statistical evaluation was carried out by using GraphPad 6.0 software. For all statistical data, level of significance was set at P < .05.
| RE SULTS
| Medium-chain fatty-acid derivative AIC-47 inhibited growth even in BCR-ABL mutant cells
As previously reported, [3] [4] [5] sensitivity to imatinib was reduced in mutant BCR-ABL (M351T, Y253F or T315I)-harboring cells ( Figure 1A ).
In contrast, AIC-47 showed significant growth inhibition even in T315I-mutated cells at the same concentration as found effective for the cells with WT-BCR-ABL ( Figure 1B ). We also examined the effect of AIC-47 on primary cells obtained from CML patients.
Imatinib showed cytotoxicity only in WT-BCR-ABL-harboring cells ( Figure 1C ). In contrast, AIC-47 led to a significant reduction in the viability of both WT-and T315I-BCR-ABL cells ( Figure 1C ). These results indicated that AIC-47 was effective regardless of the BCR-ABL mutation. In normal human bone marrow cells, imatinib showed cytotoxicity at 24 hours (P = .002), whereas AIC-47 had no effect (P = .968; Figure 1D ), suggesting that AIC-47 may be safe for use.
| AIC-47 suppressed transcription of BCR-ABL regardless of the point mutation
The greatest difference between AIC-47 and TKI was the effect of each on the expression of BCR-ABL. TKI inhibit the phosphorylation of BCR-ABL protein only, whereas AIC-47 suppresses transcription of the BCR-ABL gene. 9 Previous studies showed that c-Myc and its partner MAX bind to the promoter region of the BCR-ABL gene and play a role as a transcriptional activator of BCR-ABL. 8, 20 AIC-47 decreased c-Myc expression, leading to transcriptional suppression of WT-BCR-ABL. 8 We then examined the effects of AIC-47 on the expression of mutated-BCR-ABL mRNA. As a result, expression levels of both BCR-ABL mRNA ( 
| AIC-47 perturbed the Warburg effect through dysregulation of the PKM1/PKM2 ratio
Cancer cells efficiently use limited energy sources and anti-cancer drugs targeting cellular metabolism are expected to be useful for overcoming drug resistance. 21, 22 We reported that AIC-47 inhibits growth of CML cells through perturbation of the Warburg effect. 8 The
Warburg effect is promoted by the c-Myc/BCR-ABL/hnRNP/PKM2 signaling cascade. 8, 14, 15 In BCR-ABL-mutated cells, PKM2 protein was dominant as it was in WT-BCR-ABL-harboring cells ( Figure 3A ).
In primary CML cells, the expression of PKM2 was higher than that of PKM1 ( Figure 3A ). Expression level of PKM2 mRNA was also approximately fivefold higher than that of PKM1 ( Figure 3B ). There was no significant difference in the expression levels of PKM1 (P = .6715), PKM2 (P = .8470), and PKM (P = .4786) between WT-BCR-ABL cells and T315I-BCR-ABL-cells ( Figure 3B ). Reprogramming of the metabolic pathway has been reported to be associated with resistance to anticancer drugs; 23 however, these results suggested that the Warburg effect was achieved regardless of the point mutations in BCR-ABL and the signaling cascade was useful as a therapeutic target for overcoming TKI resistance. Consistent with previous results, AIC-47 increased the expression of PKM1, whereas it decreased that of PKM2, indicating that the PKM1/PKM2 ratio was increased in both WT-and T315-BCR-ABL-harboring cells ( Figure 3C,D) . PKM splicers PTBP1 and hnRNPA1
were decreased after treatment with AIC-47 ( Figure 3C ). Expression of SRSF3, another PKM splicer, was also markedly decreased by AIC-47 treatment ( Figure 3C ). Increase in the PKM1/PKM2 ratio was also observed by silencing of PTBP1, hnRNPA1 or SRSF3 (Figure 4 ), suggesting that AIC-47 dysregulated the Warburg effect-related signaling in both WT-and T315I-BCR-ABL-harboring cells.
| AIC-47 showed anti-leukemic effects in a leukemic mouse model
To whereas AIC-47 partly lessened this splenic infiltration ( Figure 5F ).
Together, these results suggested that AIC-47 had anti-leukemic effects in vivo regardless of BCR-ABL mutations.
| D ISCUSS I ON
In the current study, we demonstrated the effects of AIC-47 on mutated-BCR-ABL-harboring cells in vitro and in vivo. AIC-47
showed anti-leukemic effects on either WT-or mutated-BCR-ABLharboring cells ( Figure 1B,C) . Notably, imatinib showed cytotoxicity in normal human bone marrow cells, whereas AIC-47 had no such effect ( Figure 1D ). These data suggest that AIC-47 may have a higher degree of safety than TKI, but further safety testing will be needed.
Our previous studies indicated that AIC-47 had a central effect on the transcriptional suppression of BCR-ABL partly through downregulation of c-Myc, the effect of which was different from that of TKI. 9 In mutated-BCR-ABL-harboring cells, the expression levels of BCR-ABL mRNA were also suppressed by AIC-47 as in the case of F I G U R E 1 AIC-47 inhibited growth even in BCR-ABL mutant cells. A, Viability of Baf3p210 and TCCY cells treated with DMSO (Control) or imatinib for 48 h. Cells were counted after staining with Trypan-blue. Data are expressed as means ± SD of three different experiments. reported to halve the splenomegaly. 25 These findings suggested that the improvement of splenomegaly by AIC-47 might be equal to or greater than that of TKI. Survival of AIC-47-treated mice tended to be longer than that of the control mice; however, there was no significant difference between them ( Figure S2B ). To determine the effect of AIC-47 on survival, further long-term experiments will be needed.
In this leukemic mouse model, AIC-47 did not show any side-effects, including hepatotoxicity. Furthermore, no abnormal body weight loss was observed in the AIC-47-treated mice ( Figure S2C ).
We also showed that the expression of PKM2 was dominant even in BCR-ABL-mutated cells ( Figure 3A Glucose metabolism is a central source of energy for cancer, and BCR-ABL activates glycolysis and promotes glucose-dependent survival. 30 It is tempting to speculate that BCR-ABL functions as one of the key molecules of glycolysis in Ph-positive leukemia cells. Several reports showed that dysregulation of the PTBP1/PKM axis induces marked growth inhibition in various cancer cells. [31] [32] [33] In the present study, we found that hnRNPA1 and SRSF3 were also involved in the switching of PKM isoforms by AIC-47 ( Figure 3C ). Based on these findings, we speculate that cancer-specific energy metabolism, such as the Warburg effect, is one of the effective drug targets for overcoming TKI resistance of Ph-positive leukemia cells with point mutations.
There are some limitations to our investigation. We showed the Over 100 point mutations coding for single amino acid substitutions in the BCR-ABL kinase domain have been identified from CML patients resistant to imatinib treatment. 34 Nowadays, one or more TKI are available as therapy for resistance of Ph-positive leukemia with point mutations of BCR-ABL. A recent study showed that long-term outcome of patients with ponatinib failure are poor with 1-year overall survival and 1-year event-free survival, and new treatment option are needed for these patients. 7 Our data showed that AIC-47 was effective in either the presence or the absence of the mutations. In CD34 + leukemic stem cells, AIC-47 also shows a significant cytotoxic effect. 9 Our findings strongly indicate that AIC-47 might be a promising agent for overcoming TKI resistance and successfully treating Ph-positive leukemia. 
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